Wait a Second! Aspirin for Secondary Prevention in Patients with CAD and Atrial Fibrillation

<p>Laurel Lake, PharmD (<a href='https://twitter.com/laurel_pharmd'>@laurel_pharmd</a>) outlines the guideline recommendations for duration of antiplatelet therapy in acute coronary syndrome in patients using anticoagulation for atrial fibrillation, reviews recent literature examining antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease and discusses the balance of risks and benefits of antiplatelet and anticoagulant agents in these patients.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>